This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Mar;20(3):162-163.

doi: 10.1016/S1474-4422(21)00035-1.

Lessons learned from a progressive supranuclear palsy trial

Murray Grossman¹

Affiliations

Affiliation

¹ Penn Frontotemporal Degeneration Center and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: mgrossma@pennmedicine.upenn.edu.

PMID: 33609464
DOI: 10.1016/S1474-4422(21)00035-1

Comment

Lessons learned from a progressive supranuclear palsy trial

Murray Grossman. Lancet Neurol. 2021 Mar.

. 2021 Mar;20(3):162-163.

doi: 10.1016/S1474-4422(21)00035-1.

Author

Murray Grossman¹

Affiliation

¹ Penn Frontotemporal Degeneration Center and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: mgrossma@pennmedicine.upenn.edu.

PMID: 33609464
DOI: 10.1016/S1474-4422(21)00035-1

No abstract available

PubMed Disclaimer

Comment on

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H; Arise Investigators. Höglinger GU, et al. Lancet Neurol. 2021 Mar;20(3):182-192. doi: 10.1016/S1474-4422(20)30489-0. Lancet Neurol. 2021. PMID: 33609476 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information